Daniel M Altmann Selected Research

Cutaneous anthrax

1/2015	Natural cutaneous anthrax infection, but not vaccination, induces a CD4(+) T cell response involving diverse cytokines.
5/2014	Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity.
4/2010	Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel M Altmann Research Topics

Disease

25	Infections 01/2022 - 09/2002
13	COVID-19 11/2022 - 12/2020
9	Multiple Sclerosis 06/2015 - 07/2004
7	Anthrax 03/2015 - 04/2010
5	Neoplasms (Cancer) 01/2021 - 10/2018
5	Melioidosis 01/2018 - 01/2011
5	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 06/2009 - 08/2004
4	Rheumatoid Arthritis 01/2022 - 01/2006
3	Arthritis (Polyarthritis) 01/2022 - 02/2006
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 12/2012
3	Virus Diseases (Viral Diseases) 01/2022 - 01/2017
3	Inflammation (Inflammations) 01/2019 - 12/2012
3	Sepsis (Septicemia) 01/2019 - 09/2007
3	Bacterial Infections (Bacterial Infection) 11/2018 - 04/2010
3	Bronchiectasis 11/2018 - 02/2006
3	Disease Susceptibility (Diathesis) 06/2015 - 09/2009
3	Cutaneous anthrax 01/2015 - 04/2010
3	Septic Shock (Toxic Shock Syndrome) 09/2007 - 02/2004
2	Cystic Fibrosis (Mucoviscidosis) 12/2014 - 01/2011
2	Prion Diseases (Transmissible Spongiform Encephalopathies) 11/2008 - 11/2006
2	Shock 09/2007 - 11/2005
2	Paralysis (Palsy) 02/2005 - 07/2004
1	Atopic Dermatitis (Atopic Eczema) 01/2022
1	Necrosis 01/2022
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022
1	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 01/2022
1	Axial Spondyloarthritis 01/2022
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022
1	Breakthrough Infections 01/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2021
1	Reinfection 01/2021
1	Bacterial Pneumonia 12/2020
1	Elephantiasis 12/2020
1	Common Cold 01/2020
1	Insulin Resistance 01/2019
1	Obesity 01/2019
1	Overweight 01/2019
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 11/2018

Drug/Important Bio-Agent (IBA)

18	VaccinesIBA 01/2022 - 11/2006
16	EpitopesIBA 01/2020 - 07/2004
12	AntigensIBA 01/2022 - 01/2006
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2004
7	CytokinesIBA 01/2019 - 09/2005
7	Peptides (Polypeptides)IBA 05/2015 - 07/2004
6	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 11/2018 - 07/2009
5	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 07/2004
4	HLA-DR1 Antigen (HLA DR1 Antigen)IBA 04/2014 - 11/2005
3	COVID-19 VaccinesIBA 11/2022 - 01/2022
3	Anti-Bacterial Agents (Antibiotics)IBA 12/2020 - 04/2010
3	KIR ReceptorsIBA 01/2019 - 02/2006
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2019 - 06/2015
3	HLA-DR15 antigenIBA 06/2015 - 02/2005
3	Immunodominant EpitopesIBA 06/2015 - 11/2006
3	Myelin Basic ProteinIBA 02/2012 - 08/2004
3	SuperantigensIBA 09/2007 - 02/2004
2	InterferonsIBA 01/2022 - 01/2021
2	BNT162 VaccineIBA 01/2022 - 04/2021
2	HLA-DRB1 Chains (HLA DRB1)IBA 01/2022 - 06/2015
2	Biomarkers (Surrogate Marker)IBA 10/2021 - 07/2009
2	Neutralizing AntibodiesIBA 04/2021 - 12/2020
2	AntibodiesIBA 01/2021 - 05/2014
2	ClaudinsIBA 11/2018 - 06/2015
2	Combined VaccinesIBA 01/2017 - 05/2010
2	AutoantigensIBA 05/2015 - 02/2006
2	Heroin (Diamorphine)IBA 03/2015 - 02/2014
2	Anthrax Vaccines (Vaccines, Anthrax)IBA 01/2015 - 04/2010
2	AllergensIBA 04/2014 - 07/2009
2	Interleukin-17 (Interleukin 17)IBA 07/2012 - 06/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2007 - 11/2005
2	Collagen Type II (Type II Collagen)IBA 05/2007 - 02/2006
1	Infliximab (Remicade)FDA Link 01/2022
1	vedolizumabIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 01/2022
1	tofacitinibIBA 01/2022
1	HLA-DR Antigens (HLA-DR)IBA 01/2022
1	IntegrinsIBA 01/2022
1	(N- Ac- His(1)- Nle(17)- Arg(20,21)- Ala(26))- vasoactive intestinal peptideIBA 01/2022
1	Vascular Endothelial Growth Factor CIBA 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 01/2022
1	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2022
1	NucleoproteinsIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 10/2021
1	RNA (Ribonucleic Acid)IBA 10/2021
1	mRNA VaccinesIBA 04/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Oxidoreductases (Dehydrogenase)IBA 01/2021
1	SoilIBA 12/2020
1	ParaffinIBA 12/2020
1	Irritants (Vesicants)IBA 12/2020
1	Formaldehyde (Formol)FDA Link 12/2020
1	Viral AntigensIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 11/2019
1	CelluloseIBA 01/2019
1	inulin-propionate esterIBA 01/2019
1	Inulin FDA Link 01/2019
1	PropionatesIBA 01/2019
1	Interleukin-8 (Interleukin 8)IBA 11/2018

Therapy/Procedure

5	Therapeutics 01/2022 - 07/2004
5	Immunotherapy 01/2021 - 01/2006